Measurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed population

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Kusi, Kwadwo A ^a,b   Dodoo, Daniel ^b   Bosomprah, Samuel ^c   van der Eijk, Marjolein ^a   Faber, Bart W ^a   Kocken, Clemens H M ^a   Remarque, Edmond J ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b University of Ghana   (Ghana)

^c UNIVERSITY OF GHANA   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; APICAL MEMBRANE ANTIGEN 1 ANTIBODY; EPITOPE; MALARIA VACCINE; PARASITE ANTIBODY; PARASITE ANTIGEN; UNCLASSIFIED DRUG; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MEMBRANE PROTEIN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADOLESCENT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; GENETIC VARIABILITY; GHANA; HUMAN; INCIDENCE; MALARIA; PRESCHOOL CHILD; ALLELE; BLOOD; FEMALE; GENETICS; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; PLASMA;

ADOLESCENT; ALLELES; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GHANA; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALARIA; MALE; MEMBRANE PROTEINS; PLASMA; PROTOZOAN PROTEINS;

EID: 84856507895     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-32     Document Type: Article

References (38)

1. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 1994, 180:389-393. 10.1084/jem.180.1.389, 2191569, 7516416.
2. Deans JA, Alderson T, Thomas AW, Mitchell GH, Lennox ES, Cohen S. Rat monoclonal antibodies which inhibit the in vitr multiplication of Plasmodium knowles. Clin Exp Immunol 1982, 49:297-309. 1536485, 6751636.
3. Dutta S, Haynes JD, Moch JK, Barbosa A, Lanar DE. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci USA 2003, 100:12295-12300. 10.1073/pnas.2032858100, 218752, 14526103.
4. Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418:785-789. 10.1038/nature00937, 12181569.
5. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, Jepsen S, Druilhe P. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitr. Infect Immun 1998, 66:11-17. 107852, 9423833.
6. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses?. Nat Med 2005, 11:S54-S62. 10.1038/nm1216, 15812491.
7. Struik SS, Riley EM. Does malaria suffer from lack of memory?. Immunol Rev 2004, 201:268-290. 10.1111/j.0105-2896.2004.00181.x, 15361247.
8. Bousema T, Drakeley C, Gesase S, Hashim R, Magesa S, Mosha F, Otieno S, Carneiro I, Cox J, Msuya E, Kleinschmidt I, Maxwell C, Greenwood B, Riley E, Sauerwein R, Chandramohan D, Gosling R. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 2010, 201:1764-1774. 10.1086/652456, 20415536.
9. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 2011, 204:19-26. 10.1093/infdis/jir223, 21628654.
10. Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaud involve recognition of strain-specific epitopes. Infect Immun 1996, 64:3310-3317. 174223, 8757869.
11. Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci USA 2007, 104:12488-12493. 10.1073/pnas.0701464104, 1941496, 17636123.
12. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 2001, 69:3286-3294. 10.1128/IAI.69.5.3286-3294.2001, 98287, 11292751.
13. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW. In vitr studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002, 70:6948-6960. 10.1128/IAI.70.12.6948-6960.2002, 133034, 12438374.
14. Kusi KA, Faber BW, Thomas AW, Remarque EJ. Humoral immune response to mixed PAMA1 alleles; multivalent PAMA1 vaccines induce broad specificity. PLoS ONE 2009, 4:e8110. 10.1371/journal.pone.0008110, 2779588, 19956619.
15. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, Rubinstein E, Hannoun L, Charoenvit Y, Kocken CH, Thomas AW. Geert-Jan van Gemert GJ, Sauerwein RW, Blackman MJ, Anders RF, Pluschke G, Mazier D: A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 2004, 279:9490-9496. 10.1074/jbc.M311331200, 14676185.
16. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 2002, 70:6961-6967. 10.1128/IAI.70.12.6961-6967.2002, 133036, 12438375.
17. Thomas AW, Waters AP, Carr D. Analysis of variation in PF83, an erythrocytic merozoite vaccine candidate antigen of Plasmodium falciparum. Mol Biochem Parasitol 1990, 42:285-287. 10.1016/0166-6851(90)90172-I, 2270110.
18. Escalante AA, Lal AA, Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 1998, 149:189-202. 1460124, 9584096.
19. Polley SD, Chokejindachai W, Conway DJ. Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics 2003, 165:555-561. 1462796, 14573469.
20. Dodoo D, Theander TG, Kurtzhals JA, Koram K, Riley E, Akanmori BD, Nkrumah FK, Hviid L. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun 1999, 67:2131-2137. 115948, 10225865.
21. Dodoo D, Staalsoe T, Giha H, Kurtzhals JA, Akanmori BD, Koram K, Dunyo S, Nkrumah FK, Hviid L, Theander TG. Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect Immun 2001, 69:3713-3718. 10.1128/IAI.69.6.3713-3718.2001, 98376, 11349035.
22. Remarque EJ, Faber BW, Kocken CH, Thomas AW. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 2008, 76:2660-2670. 10.1128/IAI.00170-08, 2423090, 18378635.
23. Faber BW, Remarque EJ, Kocken CH, Cheront P, Cingolani D, Xhonneux F, Jurado M, Haumont M, Jepsen S, Leroy O, Thomas AW. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastori. Vaccine 2008, 26:6143-6150. 10.1016/j.vaccine.2008.08.055, 18804135.
24. Kocken CH, Withers-Martinez C, Dubbeld MA, van der WA, Hackett F, Valderrama A, Blackman MJ, Thomas AW. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002, 70:4471-4476. 10.1128/IAI.70.8.4471-4476.2002, 128198, 12117958.
25. Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat 2007, 17:571-582. 10.1080/10543400701329422, 17613642.
26. Osier FH, Weedall GD, Verra F, Murungi L, Tetteh KK, Bull P, Faber BW, Remarque E, Thomas A, Marsh K, Conway DJ. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect Immun 2010, 78:4625-4633. 10.1128/IAI.00576-10, 2976345, 20732997.
27. Polley SD, Conway DJ. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 2001, 158:1505-1512. 1461755, 11514442.
28. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, Ouattara A, Traore K, Niangaly A, Djimde AA, Doumbo OK, Plowe CV. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 2009, 1:2-5.
29. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clinical Microbiology Reviews 2009, 22:13-36. 10.1128/CMR.00025-08, 2620631, 19136431.
30. Cortes A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC, Anders RF. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect Immun 2005, 73:422-430. 10.1128/IAI.73.1.422-430.2005, 538974, 15618180.
31. Kusi KA, Faber BW, van der EM, Thomas AW, Kocken CH, Remarque EJ. Immunization with different PAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits. Malar J 2011, 10:40. 10.1186/1475-2875-10-40, 3050776, 21320299.
32. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, Heppner DG, Lanar DE, Collins WE, Barnwell JW. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotu model. PLoS ONE 2009, 4:e8138. 10.1371/journal.pone.0008138, 2780715, 19997632.
33. Kusi KA, Faber BW, Riasat V, Thomas AW, Kocken CH, Remarque EJ. Generation of humoral immune responses to multi-allele PAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS ONE 2010, 5:e15391. 10.1371/journal.pone.0015391, 2972715, 21082025.
34. Dodoo D, Aikins A, Kusi KA, Lamptey H, Remarque E, Milligan P, Bosomprah S, Chilengi R, Osei YD, Akanmori BD, Theisen M. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J 2008, 7:142. 10.1186/1475-2875-7-142, 2529305, 18664257.
35. Dodoo D, Atuguba F, Bosomprah S, Ansah NA, Ansah P, Lamptey H, Egyir B, Oduro AR, Gyan B, Hodgson A, Koram KA. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana. Malar J 2011, 10:108. 10.1186/1475-2875-10-108, 3101166, 21529376.
36. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 2010, 7:e1000218. 10.1371/journal.pmed.1000218, 2808214, 20098724.
37. Iriemenam NC, Khirelsied AH, Nasr A, Elghazali G, Giha HA, Elhassan A-E, Agab-Aldour AA, Montgomery SM, Anders RF, Theisen M, Troye-Blomberg M, Elbashir MI, Berzins K. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 2009, 27:62-71. 10.1016/j.vaccine.2008.10.025, 18977268.
38. Gatton ML, Cheng Q. Investigating antigenic variation and other parasite-host interactions in Plasmodium falciparum infections in naive hosts. Parasitology 2004, 128:367-376. 10.1017/S0031182003004608, 15151141.